Stool DNA test: pros, cons, and process
The stool DNA test, also known as Cologuard, is an at-home screening test for colorectal cancer. It tests for blood and DNA changes in the stool, which may indicate colorectal cancer.
Step by step
- Place test bracket on toilet bowl
- Place kit container in bracket
- Sit on toilet and have bowel movement into container
- Remove container and scrape stool sample with kit probe
- Place sample in tube and set aside
- Add enclosed liquid preservative to container; close tightly
- Immediately send both tube and container to testing address by mail
How it works
- Like FIT, the stool DNA test (Cologuard) detects microscopic amounts of blood in stool, but also looks for certain DNA changes that are found in cancerous tumors or precancerous polyps.
- Cells from precancerous and cancerous lesions with certain mutations often shed DNA biomarkers into the stool, where this test can detect them.
- Because DNA markers may be present in only very small quantities in stool, sensitive laboratory methods are used to detect the markers. The stool DNA test has high detection rates of early-stage colon cancer.
The pros
- Easy to use
- No special changes to diets or medicines
- No liquids/prep to drink
- Inexpensive
- Covered by most insurance
- Done in privacy of your home
- Greater accuracy than FIT
The cons
- Patients may find test unpleasant to do
- Has a high false-negative rate, which can leave colon cancer undiagnosed
- Has a high false-positive rate
- Does not provide a view of the colon and rectum
- May miss tumors that bleed in small amount or not at all
- Tests may result incorrectly in warm climates or with postal delays
- Must be repeated every year
- Follow-up colonoscopy after a positive test may not be covered by insurance
Other at-home screening tests
Fecal immunochemical test (FIT)Top resources
Legislation introduced to address young-onset CRC
Explore the urgent need for the Colorectal Cancer Early Detection Act (HR 7714), legislation aimed at combating the rising incidence of colorectal cancer among younger adults through enhanced screening, education, and research.
Dak Prescott joins Alliance to ‘LEAD FROM BEHIND’
Initiative aims to reduce stigma and educate about screening choices, as the Colorectal Cancer Alliance launches a health equity fund to decrease disparities.
Act now to create a coverage pathway for future blood-based detection
On the horizon are blood tests that have shown the ability to detect a variety of cancers including colorectal and rare cancers. Though these tests are still in development and are not yet approved by the FDA, clinical trials have shown impressive results.